Executives and stakeholders in a drug development process are interested in two main things – seeing the overview of progress and having access to the budgetary data. Execs and stakeholders need this information to reduce risk during this lengthy process. If headway of the drug development process is stalled, halted or changes in any way […]

The overall success of a team depends on whether it functions as a whole. A collaborative team works together and communicates. Transparency of work lends itself to communication among team members and across teams. Communication should span from the CEO, to top executives, to lower ranks of employees. With transparency, nothing will be missed. Having […]

Many hands go into developing a new drug and it is over the course of several years. As a result, data winds up getting lost or work is duplicated. For pharmaceuticals and CROs, internal processes can be a challenge with information scattered among various divisions each with separate tracking systems. Developing a new drug and […]

Bringing a new drug to market is not without risk. Certainly every pharmaceutical has completed rigorous analysis and determined acceptable risk tolerances for everything, from adverse events to re-submission delays. Even still, it is nerve racking making the decision to initiate new drug development research given the lengthy timelines and costs associated with a drug. […]

There are tremendous risks associated when developing a new drug. Ordinarily a drug lifecycle is between 10-12 years and teams are bound to encounter unforeseen hurdles. If teams are not utilizing the same processes and tracking their progress in the same way that can result in unforeseen delays and loss of data. It is critical […]